Patty and I just attended a presentation by Richard Hopkins, MD given for the benefit of our CHD Families support group . Dr. Hopkins is Director, Cardiac Surgery Research Laboratories at Children’s Mercy Hospital in Kansas City and is responsible for some promising research is heart valve tissue engineering.
Sophia has had a cryogenic homograft conduit placed from right ventricle to pulmonary arteries twice since she has been born. The first time the homograft failed by developing a pseudoaneurysm. This caused a second surgery to replace the failed conduit.
This type of homograft tissue, acquired from human tissue donors, has a problem of becoming calcified over time in children’s bodies causing the valves within to fail within a few years. This makes it necessary that they be replaced frequently throughout a CHD patients life which is an obvious shortcoming of the technology.
The research Dr. Hopkins is doing would take the same donor tissue and strip it of the cells that might cause problems in the recipients body leaving only a “biological scaffold”. This scaffold would be “seeded” with multi-function cells harvested from the patient’s bone marrow. Tissue would then be engineered in the laboratory over days on the scaffold. And when the engineered valve is surgically sewn into the patient, the same multi-function cells would continue to populate the structure of the valve basically growing a valve from the patients own cells. In animal trials the engineered valves do not calcify or deteriorate over time at near the rate as the cryogenic homografts.
This research is being done right here at our hospital and directly affects the type of repair Sophia has had. It is quite feasible that this biotechnology could impact directly the long term quality of Sophia’s life. We were so thankful for this presentation and wish Dr. Hopkins and his research team much success in their endeavors.
There is a little bit of info about the research here.